CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical ...

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini ...

Early research shows the CD40L antibody tegoprubart is able to reduce insulin dependence in patients with type 1 diabetes after islet transplants.

Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 Key highlights Lundbeck's total revenue grew by +13% CER[1] (+10% DKK) to DKK 16,463 milli ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Guggenheim ...

A newly designed therapy following an islet cell transplant could mean people with type 1 diabetes no longer need to inject ...

CD40（TNFRSF5）是一个48KD的跨膜蛋白，表达于三类细胞，包括抗原递呈细胞（巨噬细胞，DC细胞，B细胞），非免疫细胞（（ 肌成 ...

糖尿病，尤其是1型糖尿病（T1D），一直是一个困扰全球数百万患者的慢性疾病。许多患者每天需要注射胰岛素来控制血糖水平，这不仅给生活带来了不便，还伴随着一系列潜在的健康风险。那么，有没有可能让这些患者彻底摆脱胰岛素呢？最近的一项研究或许为我们带来了答案。 想象一下，如果有一种方法能够让糖尿病患者不再依赖胰岛素，那将是一个多么令人振奋的消息！近日，Eledon Pharmaceuticals公司公布了 ...

Eledon Pharmaceuticals shares hit their 52-week high after the company said it saw positive data for the first three islet transplant recipients treated with an immunosuppression regimen that includes ...